Search
WGc-0201
go.drugbank.com/drugs/DB22819InvestigationalWGc-0201 is under investigation in clinical trial NCT07077369 (WGc-0201 Plus Tislelizumab in HCC With High Risk of Recurrence and Metastasis After Radical Therapy).
RSV-604
go.drugbank.com/drugs/DB15197InvestigationalRSV-604 is under investigation in clinical trial NCT00416442 (Safety, Tolerability and Pharmacokinetic Study of Single and Multiple Intravenous Doses of RSV604 in Healthy Subjects.).
Pegteograstim
go.drugbank.com/drugs/DB15290InvestigationalPegteograstim is under investigation in clinical trial NCT02787876 (Pegteograstim in Children With Solid Tumors).
Parsatuzumab
go.drugbank.com/drugs/DB14897InvestigationalParsatuzumab is under investigation in clinical trial NCT01366131 (Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced
Cabamiquine
go.drugbank.com/drugs/DB21477InvestigationalCabamiquine is under investigation in clinical trial NCT05974267 (Efficacy, Safety, and PK of M5717 in Combination With Pyronaridine as Chemoprevention in Adults and Adolescents With Asymptomatic Plasmodium
Mevastatin
go.drugbank.com/drugs/DB06693ExperimentalDuring a search for antibiotic compounds produced by fungi in 1971, Akira Endo at Sankyo Co. (Japan) discovered a class of compounds that appeared to lower plasma cholesterol levels. … Mevastatin is a pro-drug that is activated by <i>in vivo</i> hydrolysis of the lactone ring. It has served as one of the lead compounds for the development of the synthetic compounds used today.
AICA ribonucleotide
go.drugbank.com/drugs/DB01700Investigational5-Aminoimidazole-4-carboxamide ribonucleotide (AICAR) is an intermediate in the generation of inosine monophosphate and analog of adenosine monophosphate (AMP) that is capable of stimulating AMP-dependent … The drug was first used in the 1980s as a method to preserve blood flow to the heart during surgery and is currently of interest as a potential treatment for diabetes by increasing the metabolic activity
Lerociclib
go.drugbank.com/drugs/DB16218InvestigationalLerociclib is under investigation in clinical trial NCT02983071 (G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-positive, Her2-negative Locally Advanced or Metastatic Breast
EB05
go.drugbank.com/drugs/DB16477InvestigationalEB05, in combination with standard of care (SOC), is being investigated in clinical trial NCT04401475 to evaluate its safety and efficacy in adult hospitalized patients with COVID-19 and ARDS.